Prion protein: Structural features and related toxicity

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 6, 2013, Pages 435-441

  Hu, Ping Ping ^a   Huang, Cheng Zhi ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Amyloid; Oligomer; Prion protein; Toxicity

Indexed keywords

AMYLOID; BIOPOLYMER; OLIGOMER; PRION PROTEIN;

ANIMAL; BRAIN DISEASE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; PRION; PROTEIN CONFORMATION; REVIEW; TOXICITY;

AMYLOID; OLIGOMER; PRION PROTEIN; TOXICITY;

ANIMALS; BIOPOLYMERS; BRAIN DISEASES; HUMANS; MODELS, MOLECULAR; PRIONS; PROTEIN CONFORMATION;

EID: 84879210441     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt035     Document Type: Review

References (89)

1. Prusiner S. Novel proteinaceous infectious particles cause scrapie. Science 1982, 216: 136-144.
2. Chesebro B. Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 2003, 66: 1-20.
3. Will R, Ironside J, Zeidler M, Cousens S, Estibeiro K, Alperovitch A and Poser S, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996, 347: 921-925.
4. Prusiner S. Prions. Proc Natl Acad Sci USA 1998, 95: 13363-13383.
5. Ma J and Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002, 298: 1785-1788.
6. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D and Mehlhorn I, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993, 90: 10962-10966.
7. Satoshi D, Masako I, Morikazu S, Gihei S, Isomura H and Goto H. Western Blot Detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice. J Gen Virol 1988, 69: 955-960.
8. Collinge J. Prion disease of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001, 24: 519-550.
9. Prusiner SB, Scott MR, DeArmond SJ and Cohen FE. Prion protein biology. Cell 1998, 93: 337-348.
10. Brandner S, Raeber A, Sailer A, Blättler T, Fischer M, Weissmann C and Aguzzi A. Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proc Natl Acad Sci USA 1996, 93: 13148-13151.
11. Büeler H, Aguzzi A, Sailer A, Greiner R-A, Autenried P, Aguet M and Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993, 73: 1339-1347.
12. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y and Marino S, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996, 379: 339-343.
13. Mallucci G, Dickinson A, Linehan J, Klöhn P, Brandner S and Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003, 302: 871-874.
14. Rambold AS, Mü ller V, Ron U, Ben-Tal N, Winklhofer KF and Tatzelt J. Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J 2008, 27: 1974-1984.
15. Silveira J, Raymond G, Hughson A, Race R, Sim V, Hayes S and Caughey B. The most infectious prion protein particles. Nature 2005, 437: 257-261.
16. Kim C, Haldiman T, Surewicz K, Cohen Y, Chen W, Blevins J and Sy M-S, et al. Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrP(C). PLoS Pathog 2012, 8: e1002835.
17. Lasagna-Reeves CA, Glabe CG and Kayed R. Amyloid-b annular protofibrils evade fibrillar fate in Alzheimer disease brain. J Biol Chem 2011, 286: 22122-22130.
18. Stefani M and Dobson CM. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J Mol Med 2003, 81: 678-699.
19. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW and Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300: 486-489.
20. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R and Wüthrich K. NMR structure of the mouse prion protein domain PrP (121-231). Nature 1996, 382: 180-182.
21. Stahl N, Borchelt D, Hsiao K and Prusiner S. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987, 51: 229-240.
22. Madore N, Smith KL, Graham CH, Jen A, Brady K, Hall S and Morris R. Functionally different GPI proteins are organized in different domains on the neuronal surface. EMBO J 1999, 18: 6917-6926.
23. Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY and Kascsak RJ, et al. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 1992, 42: 149-156.
24. Málaga-Trillo E, Solis GP, Schrock Y, Geiss C, Luncz L, Thomanetz V and Stuermer CAO. Regulation of embryonic cell adhesion by the prion protein. PLoS Biol 2009, 7: e1000055.
25. Stahl N, Baldwin M, Teplow D, Hood L, Gibson B, Burlingame A and Prusiner S. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 1993, 32: 1991-2002.
26. Oesch B, Westaway D, Wälchli M, McKinley MP, Kent SBH, Aebersold R and Barry RA, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985, 40: 735-746.
27. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H and Serban A, et al. Diagnosis of human prion disease. Proc Natl Acad Sci USA 2005, 102: 3501-3506.
28. McKinley M, Meyer R, Kenaga L, Rahbar F, Cotter R, Serban A and Prusiner S. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J Virol 1991, 65: 1340-1351.
29. Prusiner S, McKinley M, Bowman K, Bolton D, Bendheim P, Groth D and Glenner G. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983, 35: 349-358.
30. Bartz JC, Bessen RA, McKenzie D, Marsh RF and Aiken JM. Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy. J Virol 2000, 74: 5542-5547.
31. Peretz D, Scott MR, Groth D, Williamson RA, Burton DR, Cohen FE and Prusiner SB. Strain-specified relative conformational stability of the scrapie prion protein. Protein Sci 2001, 10: 854-863.
32. Spraker TR, Balachandran A, Zhuang D and O'Rourke KI. Variable patterns of distribution of PrP CWD in the obex and cranial lympoid tissues of rock mountain elk (Cervus elaphus nelsoni) with subclinical chronic wasting disease. Vet Rec 2004, 155: 295-302.
33. Aguzzi A. Prions and the immune system: a journey through gut, spleen, and nerves. Adv Immunol 2003, 81: 123-171.
34. Griffith J. Self-replication and scrapie. Nature 1967, 215: 1043-1044.
35. Morales R, Abid K and Soto C. The prion strain phenomenon: Molecular basis and unprecedented features. Biochim Biophys Acta 2007, 1772: 681-691.
36. Pattison IH and Millson GC. Scrapie produced experimentally in goats with special reference to the clinical syndrome. J Comp Pathol 1961, 71: 101-109.
37. Bruce M. Scrapie strain variation and mutation. Br Med Bull 1993, 49: 822-838.
38. Bruce ME, Boyle A, Cousens S, McConnell I, Foster J, Goldmann W and Fraser H. Strain characterization of natural sheep scrapie and comparison with BSE. J Gen Virol 2002, 83: 695-704.
39. Lasmzas CI, Deslys J-P, Demaimay R, Adjou KT, Hauw J-J and Dormont D. Strain specific and common pathogenic events in murine models of scrapie and bovine spongiform encephalopathy. J Gen Virol 1996, 77: 1601-1609.
40. Muramoto T, Kitamoto T, Tateishi J and Goto I. Successful transmission of Creutzfeldt-Jakob disease from human to mouse verified by prion protein accumulation in mouse brains. Brain Res 1992, 599: 309-316.
41. Schoch G, Seeger H, Bogousslavsky J, Tolnay M, Janzer RC, Aguzzi A and Glatzel M. Analysis of prion strains by PrPSc profiling in sporadic Creutzfeldt-Jakob disease. PLoS Med 2006, 3: e14.
42. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett 2001, 498: 204-207.
43. Soto C and Estrada L. Protein misfolding and neurodegeneration. Arch Neurol 2008, 65: 184-189.
44. Caughey B and Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003, 26: 267-298.
45. Haass C and Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007, 8: 101-112.
46. Soto C, Estrada L and Castilla J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 2006, 31: 150-155.
47. Jarrett JT and Lansbury PT. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 1993, 73: 1055-1058.
48. Sokolowski F, Modler AJ, Masuch R, Zirwer D, Baier M, Lutsch G and Moss DA, et al. Formation of critical oligomers is a key event during conformational transition of recombinant Syrian hamster prion protein. J Biol Chem 2003, 278: 40481-40492.
49. Prusiner SB. A unifying role for prions in neurodegenerative diseases. Science 2012, 336: 1511-1513.
50. Modler A, Fabian H, Sokolowski F, Lutsch G, Gast K and Damaschun G. Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation. Amyloid 2004, 11: 215-231.
51. DeMarco ML and Daggett V. From conversion to aggregation: protofibril formation of the prion protein. Proc Natl Acad Sci USA 2004, 101: 2293-2298.
52. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A and Benedek GB, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999, 274: 25945-25952.
53. Srinivasan R, Marchant R and Zagorski M. ABri peptide associated with familial British dementia forms annular and ring-like protofibrillar structures. Amyloid 2004, 11: 10-13.
54. Lashuel HA, Hartley D, Petre BM, Walz T and Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418: 291.
55. Modler AJ, Gast K, Lutsch G and Damaschun G. Assembly of amyloid protofibrils via critical oligomers - a novel pathway of amyloid formation. J Mol Biol. 2003, 325: 135-148.
56. Winkler J, Tyedmers J, Bukau B and Mogk A. Chaperone networks in protein disaggregation and prion propagation. J Struct Biol 2012, 179: 152-160.
57. Hetz C, Russelakis-Carneiro M, Maundrell K, Castilla J and Soto C. Caspase-12 and endoplasmic reticulum stress mediate neurotoxicity of pathological prion protein. EMBO J 2003, 22: 5435-5445.
58. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 1993, 362: 543-546.
59. Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner S, Götz J and Rülicke T, et al. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 1998, 93: 203-214.
60. Solomon IH, Huettner JE and Harris DA. Neurotoxic mutants of the prion protein induce spontaneous ionic currents in cultured cells. J Biol Chem 2010, 285: 26719-26726.
61. Soto C and Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol Med 2010, 17: 14-24.
62. Lasmézas CI, Deslys J-P, Robain O, Jaegly A, Beringue V, Peyrin J-M and Fournier J-G, et al. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997, 275: 402-405.
63. Piccardo P, Manson JC, King D, Ghetti B and Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci USA 2007, 104: 4712-4717.
64. Chiesa R, Piccardo P, Biasini E, Ghetti B and Harris DA. Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci 2008, 28: 13258-13267.
65. Safar J, Ceroni M, Piccardo P, Gajdusek DC and Gibbs CJ. Scrapie-associated precursor proteins antigenic relationship between species and immunocytochemical localization in normal, scrapie, and Creutzfeldt-Jakob disease brains. Neurology 1990, 40: 513-517.
66. Cortes CJ, Qin K, Cook J, Solanki A and Mastrianni JA. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Sträussler-Scheinker disease. J Neurosci 2012, 32: 12396-12405.
67. Masel J, Genoud N and Aguzzi A. Efficient inhibition of prion replication by PrP-Fc2 suggests that the prion is a PrPSc oligomer. J Mol Biol. 2005, 345: 1243-1251.
68. Masel J, Jansen V and Nowak M. Quantifying the kinetic parameters of prion replication. Biophys Chem 1999, 77: 139-152.
69. Grenier C, Bissonnette C, Volkov L and Roucou X. Molecular morphology and toxicity of cytoplasmic prion protein aggregates in neuronal and nonneuronal cells. J Neurochem 2006, 97: 1456-1466.
70. Kristiansen M, Deriziotis P, Dimcheff DE, Jackson GS, Ovaa H, Naumann H and Clarke AR, et al. Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell 2007, 26: 175-188.
71. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB and Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2002, 100: 330-335.
72. Zhu M, Han S, Zhou F, Carter SA and Fink AL. Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy. J Biol Chem 2004, 279: 24452-24459.
73. Kazlauskaite J, Young A, Gardner CE, Macpherson JV, Vénien-Bryan C and Pinheiro TJT. An unusual soluble b-turn-rich conformation of prion is involved in fibril formation and toxic to neuronal cells. Biochem Biophys Res Commun 2005, 328: 292-305.
74. Novitskaya V, Bocharova O, Bronstein I and Baskakov I. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 2006, 281: 13828-13836.
75. Bueler H, Raeber A, Sailer A, Fischer M, Aguzzi A and Weissmann C. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med 1994, 1: 19-30.
76. Resenberger U, Harmeier A, Woerner A, Goodman J, Mü ller V, Krishnan R and Vabulas R, et al. The cellular prion protein mediates neurotoxic signalling of b-sheet-rich conformers independent of prion replication. EMBO J 2011, 30: 2057-2070.
77. Simoneau S, Rezaei H, Salès N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C and Fournier J, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog 2007, 3: e125.
78. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR and Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011, 470: 540-542.
79. Solomon IH, Biasini E and Harris DA. Ion channels induced by the prion protein. Prion 2012, 6: 40-45.
80. Lin M-C, Mirzabekov T and Kagan BL. Channel formation by a neurotoxic prion protein fragment. J Biol Chem 1997, 272: 44-47.
81. Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B and Kagan B, et al. Amyloid ion channels: a common structural link for proteinmisfolding disease. Proc Natl Acad Sci USA 2005, 102: 10427-10432.
82. Madampage C, Tavassoly O, Christensen C, Kumari M and Lee JS. Nanopore analysis: an emerging technique for studying the folding and misfolding of proteins away. Prion 2012, 6: 116-123.
83. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE and Glabe CG. Permeabilization of lipid bilayers is a common conformationdependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004, 279: 46363-46366.
84. Kourie JI and Henry CL. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: the role of dangerous unchaperoned molecules. Clin Exp Pharmacol Physiol 2002, 29: 741-753.
85. Kawahara M, Kuroda Y, Arispe N and Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 2000, 275: 14077-14083.
86. Magzoub M, Oglecka K, Pramanik A, Eriksson LEG and Gräslund A. Membrane perturbation effects of peptides derived from the N-termini of unprocessed prion proteins. Biochim Biophys Acta 2005, 1716: 126-136.
87. Sassoon J, Daniels M and Brown DR. Astrocytic regulation of NMDA receptor subunit composition modulates the toxicity of prion peptide PrP106-126. Mol Cell Neurosci 2004, 25: 181-191.
88. Ratté S, Prescott SA, Collinge J and Jefferys JGR. Hippocampal bursts caused by changes in NMDA receptor-dependent excitation in a mouse model of variant CJD. Neurobiol Dis 2008, 32: 96-104.
89. Khosravani H, Zhang Y, Tsutsui S, Hameed S, Altier C, Hamid J and Chen L, et al. Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol 2008, 181: 551-565. Southwest China University